Cyteir Therapeutics, Inc. (CYT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Lexington, MA, United States. El CEO actual es Markus F. Renschler.
CYT tiene fecha de IPO 2021-06-18, 46 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $108.71M.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
